Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219734 · ClinicalTrials.gov registry record
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
A clinical trial of Cancer and Non-Small Cell Lung Cancer, sponsored by Invitae Corporation.
- Active
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT05219734 is a study of Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Invitae Corporation. The registered enrollment target is 400 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05219734, a study of Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Invitae Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Personalized Cancer Monitoring (PCM)
Study Locations (2)
Indiana
- Columbus Regional Health - Columbus
North Carolina
- Onslow Radiation - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219734
The ClinicalTrials.gov registry entry for NCT05219734 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Invitae Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Personalized Cancer Monitoring (PCM) is the first listed.
NCT05219734 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05219734 about?
NCT05219734 is a clinical study titled "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment". This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood ov...
What is the current status of trial NCT05219734?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-11-29. Estimated completion is 2026-12.
What conditions does trial NCT05219734 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Bladder Cancer.
What interventions are being tested in trial NCT05219734?
The interventions under investigation include: Personalized Cancer Monitoring (PCM) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05219734?
This trial is sponsored by Invitae Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219734 being conducted?
This trial has 2 study locations across Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.